Anti Cd 20 Ocrevus denied due to quantity / dose limits by Cigna?

Cigna's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Applies Quantity Limits to Ocrelizumab

Ocrelizumab (Ocrevus) is administered by intravenous infusion on a schedule defined by the FDA-approved prescribing information. Cigna's quantity-limit policy ties the number of vials or infusion cycles it will cover in a given period to that FDA-labeled schedule. A quantity-limit denial is issued when the amount billed appears to exceed what Cigna's policy allows — for example, if dosing intervals were adjusted by your neurologist for clinical reasons, or if a billing or coding discrepancy created an apparent overage.

## Why This Denial Is Appealable

Quantity-limit policies are meant to track the FDA-approved regimen, not to substitute the insurer's judgment for your neurologist's. If your prescriber has adjusted your dosing for a documented clinical reason, or if the denial reflects a coding error rather than an actual overage, the denial can be challenged. The appeal must show either that the amount billed matches the standard labeled regimen, or that a deviation is medically necessary and supported by the clinical record.

## Your Federal Appeal Rights

• Internal appeal: ERISA §503 and ACA §2719 entitle you to a full-and-fair internal review. File within the deadline shown on your denial notice.
• External review: If the internal appeal fails, an independent external reviewer can assess whether the quantity limit was applied correctly under ACA §2719. This avenue is generally available for approximately four months after final internal denial.
• Expedited option: If a dosing gap would cause meaningful clinical harm, request expedited review; decisions are typically required within 72 hours.

## Documentation to Gather

1. Prescribing information — obtain the current FDA-approved label and identify the standard infusion schedule. If your regimen matches it, document that directly. 2. Prescriber letter explaining any deviation from the standard schedule, citing the specific clinical reason documented in the chart. 3. Infusion records — dates and amounts of all prior infusions, showing the actual treatment timeline. 4. Billing and coding verification — confirm with the infusion center that the units billed are accurate and match the vials actually administered. 5. Cigna's quantity-limit policy — request the written policy and confirm exactly what limit was applied and how it was calculated.

## Criteria-Mapping Approach

Build a table comparing the FDA-labeled dosing schedule (left column) against your actual infusion dates and amounts (right column). If the amounts match, the denial is unsupported. If there is a clinically justified variation, add a third column citing the specific chart note or prescriber rationale. Present this mapping with the appeal letter so the reviewer can see immediately whether a true overage exists.

## Next Step

Start by confirming with your infusion center whether the units billed were correct. A billing error is the fastest path to resolution and may not require a formal clinical appeal at all. If the dosing genuinely differs from the label, your neurologist's documented rationale is the cornerstone of the appeal.